Sepsis, April 2025 edition

The study created a mass-spectrometry-based atlas linking circulating plasma proteins to their tissue and cellular origins across 18 vascularized organs and major blood-cell populations. Disease- and organ-enriched protein panels were validated across six clinical cohorts, including sepsis. The resource enables organ-specific interpretation of plasma changes and supports precision monitoring of sepsis-associated organ injury.

Impact: The paper provides a scalable biological framework for moving sepsis diagnostics beyond nonspecific inflammation toward identification of the dominant injured organ and biologically meaningful disease trajectories.

Clinical Implications: Organ-specific plasma panels could eventually support earlier detection of kidney, liver, lung, or endothelial injury, response monitoring, and selection of organ-directed interventions. Clinical deployment requires assay simplification, rapid turnaround, prospective validation, and demonstration that biomarker-guided decisions improve outcomes.

In macrophage models and cecal ligation and puncture mice, GL-V9 reduced inflammatory injury and mortality by inhibiting ALOX12-mediated lipid peroxidation upstream of Caspase-11 activation. The compound also prevented lipopolysaccharide release from early endosomes. Genetic loss of ALOX12 eliminated additional treatment benefit, supporting mechanistic specificity.

Impact: The study identifies a genetically supported, druggable checkpoint controlling non-canonical inflammasome activation and pyroptosis, offering a mechanistically focused route for host-directed sepsis therapy.

Clinical Implications: ALOX12 inhibition or GL-V9 analogues may be explored as adjunctive therapies, but translation requires pharmacokinetic and pharmacodynamic studies, large-animal validation, evaluation of infection-control effects, and careful assessment of immunosuppression risk.

This multicenter randomized non-inferiority trial enrolled 261 neonates with culture-proven sepsis who had clinically improved by day 7. A seven-day antibiotic regimen was non-inferior to 14 days for relapse within 21 days after treatment completion and reduced the median hospital stay by four days. The results provide direct evidence for shorter treatment in a carefully defined neonatal population.

Impact: This is a practice-relevant multicenter randomized trial showing that selected neonates with culture-proven sepsis may not require prolonged antibiotic therapy, with potential benefits for hospital capacity, cost, antimicrobial resistance, and drug toxicity.

Clinical Implications: A seven-day regimen can be considered only for patients meeting the trial criteria, including adequate birth weight, culture-proven infection, clinical remission by day 7, and appropriate follow-up. The findings should not be extrapolated to clinically unstable infants, meningitis, deep-seated infection, or persistent bacteremia without additional evidence.

Using bicarbonate-containing physiologic media, fresh human blood, and a murine bacteremia model, the study found that colistin retained bactericidal activity against mcr-1-positive Escherichia coli, Klebsiella pneumoniae, and Salmonella enterica. Colistin enhanced complement deposition and synergized with serum, despite conventional susceptibility testing suggesting limited activity. The findings indicate that standard AST may miss clinically relevant host–drug interactions.

Impact: This translational work challenges conventional AST paradigms and may reopen a therapeutic option for selected mcr-positive bloodstream infections when interpreted together with host complement function.

Clinical Implications: Clinical use of colistin should not be changed solely on the basis of this preclinical evidence. However, microbiology laboratories and clinicians should recognize the limitations of standard AST, investigate physiologic-condition testing, and pursue prospective clinical studies that integrate pathogen genotype, complement competence, and toxicity risk.

Using four international derivation cohorts and independent validation in an RCT dataset, investigators identified two reproducible hospital-acquired pneumonia subphenotypes. The higher-risk phenotype showed worse physiology, greater inflammation, respiratory microbiome dysbiosis, higher 28-day mortality, and more treatment failure. Subphenotype assignment also modified antibiotic effects, supporting prognostic and predictive enrichment.

Impact: The study provides an externally validated and biologically coherent framework for identifying high-risk hospital-acquired respiratory infection and selecting patients most likely to benefit from specific treatments or intensified monitoring.

Clinical Implications: Rapid subphenotype classification could support escalation decisions, closer monitoring, and phenotype-enriched clinical trials. Before routine use, the classifier requires prospective implementation studies, assessment of turnaround time and calibration across settings, and proof that treatment selection based on phenotype improves outcomes.